A Multicentre External Beam Radiotherapy Study Using Stereotactic Boost for Prostate Cancer Patients

Phase 2

Completed

• Conditions: Prostate Cancer; Cancer - Prostate

• Registration Number: ACTRN12615000223538
• Lead Sponsor: Dr Mark Sidhom

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-03-09
• Study Completion: 2023-02-28
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 129

Inclusion Criteria

1. Patient capable of giving informed consent
2. Histological diagnosis of prostate cancer (PC)
3. Intermediate or High risk disease respectively defined by any one of:
a.Baseline PSA 10-20, Gleason grade 7 disease, Clinical stage T2b-c OR
b.Baseline PSA greater than or equal to 20, Gleason grade 8-10 disease, Clinical stage T3
4. For high risk patients, negative conventional staging in the form of a:
a. PSMA PET scan OR
b. T99m whole body bone scan AND
b. Either CT of the abdomen and pelvis or MRI pelvis
5. No previous pelvic radiotherapy

Exclusion Criteria

1. ECOG performance status >1
2. Hip prosthesis
3. Inability to have intraprostatic fiducials inserted.
4. Inability to have a MRI due to:
a. Implanted magnetic metal eg intraocular metal
b. Pacemaker / Implantable defibrillator
c. Extreme claustrophobia
5. Clinical stage T4 (tumour invasion into adjacent anatomical structures)
6. Inflammatory bowel disease
7. Severe obstructive urinary symptoms
8. Inability to meet planning objectives

Study & Design

• Study Type: Interventional
• Study Design: Not specified